rare disease therapeutics Archives

Futuristic biotech illustration featuring a glowing digital bull, rising market arrows, and research pathways labeled Disc Medicine, Arcutis and Parabilis leading toward a biotechnology innovation hub.

Biotech Bulls Find Fresh Fuel as Disc Medicine, Arcutis and Parabilis Advance Their Investment Cases -( $ARQT $BBC $IRON $PBLS )

by John F. Heerdink, Jr. October 19, 2026 465Views 0Likes

A pivotal trial victory, a growing dermatology franchise and an approaching oncology catalyst put IRON, ARQT and PBLS in the spotlight, while the BBC biotech ETF offers a broader view of the sector. October 19, 2026 Biotechnology investors are being offered three…

The Biotech IPO Window Is Open, and Parabilis Medicines Walked Through With $770 Million -( $ADRX $BRVE $ETRA $KLRA $JNJ $PBLS $REGN )

by John F. Heerdink, Jr. October 3, 2026 452Views 0Likes

Parabilis Medicines, Inc. (NASDAQ: PBLS) entered public markets with the kind of financial runway, strategic endorsement and clinical ambition that tends to make biotech investors sit up straighter in their Aeron chairs. The Cambridge-based clinical-stage company is pursuing a deceptively simple proposition: use…

Biotech’s Bullish Blueprint: Jazz Pharmaceuticals Buys Actio For ~$1.3B, While Eupraxia Builds for Scale -( $EPRX $JAZZ $XBI )

by John F. Heerdink, Jr. August 11, 2026 281Views 0Likes

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) offer investors two distinctly attractive versions of the same biotech proposition: value creation through disciplined execution. Jazz is deploying capital to deepen an established rare-epilepsy franchise, while Eupraxia is assembling the…

Tag: rare disease therapeutics

Biotech Bulls Find Fresh Fuel as Disc Medicine, Arcutis and Parabilis Advance Their Investment Cases -( $ARQT $BBC $IRON $PBLS )

The Biotech IPO Window Is Open, and Parabilis Medicines Walked Through With $770 Million -( $ADRX $BRVE $ETRA $KLRA $JNJ $PBLS $REGN )

Biotech’s Bullish Blueprint: Jazz Pharmaceuticals Buys Actio For ~$1.3B, While Eupraxia Builds for Scale -( $EPRX $JAZZ $XBI )

Your Guide To Staying Informed In The Markets